Loading...
NPI 1265488563 · Liverpool, NY · Ambulatory Surgical Clinic/Center
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Syracuse Asc, LLC is a ambulatory surgical clinic/center provider located in Liverpool, New York. This profile covers 23 Medicare and 2 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Syracuse Asc, LLC |
| Address | 225 Greenfield Pkwy |
| City | Liverpool |
| State | NY |
| ZIP | 13088 |
| Taxonomy | Ambulatory Surgical Clinic/Center |
| NPI Enumerated | May 26, 2006 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $5M |
| Medicaid | $1.8M |
SYRACUSE ASC, LLC is an ambulatory surgical clinic/center whose paid claims mix is heavily ophthalmic: top billed procedures and supplies are cataract extraction with intraocular lens insertion (66984, 66982), intraoperative ophthalmic irrigation/medications (J1097, J2403), and a range of posterior-segment and corneal procedures (67042, V2785, 65756). This code mix indicates the facility operates as a high-throughput outpatient eye surgery center focused on cataract surgery and related anterior- and posterior-segment ophthalmic care rather than broad multispecialty surgery.
Revenue concentration on Medicare is high and tightly focused: the precomputed top 3 Medicare codes by revenue account for 73.2% of this provider's total Medicare revenue, driven by 66984 (45.9%), J1097 (16.3%), and J2403 (11.0%). This concentration shows most Medicare dollars flow from a small set of ophthalmic surgical and supply codes, making performance and reimbursement for those specific codes strategically important.
On Medicaid the provider is effectively mono-line: the precomputed top 3 Medicaid codes account for 100.0% of its total Medicaid revenue, with 66984 alone representing $1.8M and 99.3% of Medicaid revenue and 66982 contributing the remaining 0.7%. Medicaid reimbursement is therefore overwhelmingly dependent on cataract extraction with lens insertion in this facility.
Payer mix is skewed toward Medicare in absolute scale: lifetime Medicare revenue is $5M compared with $1.8M in Medicaid, so Medicare represents the larger revenue pool while Medicaid is a smaller but present payer. Both payers have activity, but analyses and contracting efforts should prioritize Medicare given its larger contribution to lifetime revenue.
Competitive standing on Medicare is notable for several codes: 66984 ranks #528 of 15965 providers nationally (97th percentile; notably above typical national volume), J1097 ranks #4 of 443 providers nationally (99th percentile; extreme outlier), and J2403 ranks #3 of 76 providers nationally (97th percentile; notably above typical national volume). These rankings identify the ASC as a national high-volume outlier for certain ophthalmic drug/supply and cataract procedure codes, suggesting regional or referral-driven dominance for those services.
In-state (Medicaid) competitive signals are more modest: 66984 ranks #18 of 156 providers in-state (89th percentile; typical, unremarkable volume) while 66982 ranks #26 of 31 providers in-state (13th percentile; typical, unremarkable volume). That pattern implies the clinic is a solid but not dominant Medicaid cataract provider within New York, despite being a national leader on some Medicare measures.
Operational detail from code-level patterns suggests workflow and supply intensity consistent with a high-volume cataract ASC: the very large counts and revenue for J1097 and J2403 reflect routine, high-frequency use of ophthalmic irrigation/medication products during procedures, and V2785 revenue indicates participation in corneal tissue processing/handling. These service-line characteristics imply resource planning should emphasize ophthalmic device/supply inventory, perioperative medication management, and specialty staffing for eye surgery.
The provider has an established tenure: NPI enumerated 2006-05-26 (~20 years ago), indicating long-standing operation in the market. Combined with concentrated revenue on recurrent ophthalmic procedures and high national ranks for core codes, the data point to a stable, specialized ASC with a focused cataract surgery business model.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
23 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 66984 | The provider inserts an artificial lens after removing an extracapsular cataract by aspiration or use of ultrasonic waves. This procedure is done without the use of an endoscopic laser probe to… | 2,910 | $840 | $2.4M |
| J1097 | phenylephrine 10.16 mg/ml and ketorolac 2.88 mg/ml ophthalmic irrigation solution, 1 ml | 11,370 | $80 | $864.3K |
| J2403 | Chloroprocaine hcl ophthalmic, 3% gel, 1 mg | 584,000 | $1 | $584K |
| 66982 | The provider inserts an intraocular lens prosthesis after extracapsular cataract extraction using complex techniques and devices. He may perform this by means of an iris expansion device, providing… | 290 | $820 | $240.2K |
| 66991 | The provider inserts an intraocular lens prosthesis during the same session as extracapsular cataract extraction. The provider also inserts one or more anterior segment aqueous drainage devices in… | 90 | $2,520 | $226.9K |
| V2785 | Processing, preserving and transporting corneal tissue | 70 | $3,160 | $211.7K |
| 66821 | The provider removes the haziness from the capsule of the eye using a laser for a patient with a secondary membranous cataract. | 830 | $190 | $156K |
| 67042 | In this procedure, the provider removes vitreous humor, the gelatinous material that gives shape to the eye, using a mechanical cutting tool. He removes the internal limiting membrane of the retina… | 90 | $1,510 | $133.1K |
| 65756 | During this procedure, the provider performs a complete corneal transplant to replace a damaged corneal endothelium. | 60 | $1,530 | $90.5K |
| 67036 | The provider removes vitreous fluid from the eye to access the posterior segment of the eye and introduce surgical instruments through incisions in the pars plana. | 40 | $1,530 | $67.4K |
Showing 1–10 of 23
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 23 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
23 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| J1096 | 6 | 10 | 740 | $100 | $227.3K |
| J1097 | 2 | 20 | 500 | $80 | $200.1K |
| V2785 | 3 | 10 | 70 | $3,430 | $164.6K |
| J2403 | 1 | 10 | 204,000 | $1 | $151K |
| 66984 | 10 | 680 | 90 | $430 | $104.3K |
| 66991 | 3 | 50 | 30 | $1,830 | $65.9K |
| 0275T | 24 | 30 | 20 | $2,170 | $60.8K |
| 65820 | 19 | 90 | 30 | $1,170 | $48K |
| 66989 | 8 | 10 | 20 | $2,100 | $39.8K |
| 66982 | 7 | 280 | 30 | $760 | $35.6K |
Showing 1–10 of 23
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
2 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 66984 | The provider inserts an artificial lens after removing an extracapsular cataract by aspiration or use of ultrasonic waves. This procedure is done without the use of an endoscopic laser probe to… | 1,900 | $930 | $1.8M |
| 66982 | The provider inserts an intraocular lens prosthesis after extracapsular cataract extraction using complex techniques and devices. He may perform this by means of an iris expansion device, providing… | 20 | $820 | $12.2K |
How this provider's Medicaid billing volume and revenue compare to other New York providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. New York median
2 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 66984 | The provider inserts an artificial lens after removing an extracapsular cataract by aspiration or use of ultrasonic waves. This procedure is done without the use of an endoscopic laser probe to… | 18 | 160 | 140 | $720 | $423.8K |
| 66982 | The provider inserts an intraocular lens prosthesis after extracapsular cataract extraction using complex techniques and devices. He may perform this by means of an iris expansion device, providing… | 26 | 30 | 70 | $570 | $128.4K |
Other providers in the same ZIP code as Syracuse Asc, LLC, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Laboratory Alliance Of Central New York, LLC | NY | Clinical Medical Laboratory | $2.6M | $10.6M |
| Digestive Disease Center Of Central New York, LLC | NY | Ambulatory Surgical Clinic/Center | $706K | $3.6M |
| Kevin Rosenberg | NY | Retina Specialist (Ophthalmology) Physician | $4M | $306.5K |
| Jamin Brown | NY | Retina Specialist (Ophthalmology) Physician | $3.5M | $228.9K |
| Patrick Oellers | NY | Retina Specialist (Ophthalmology) Physician | $3.5M | $161K |
| Tahsin Choudhury | NY | Retina Specialist (Ophthalmology) Physician | $3.4M | $197.9K |
| Samuel Spalding | NY | Retina Specialist (Ophthalmology) Physician | $2.3M | $28.3K |
| Mark Breazzano | NY | Retina Specialist (Ophthalmology) Physician | $2.1M | $32.7K |
| Rajeev Seth | NY | Retina Specialist (Ophthalmology) Physician | $2.1M | $15.3K |
| Bryan Rutledge | NY | Retina Specialist (Ophthalmology) Physician | $1.6M | $68.8K |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.